TandemAI just secured a fresh $22M Series A extension, and it feels like watching a lab built on physics, peptides, and pure conviction step into a brighter spotlight that was waiting for it anyway. V Capital and KHK Fund led the round, with the returning belief of OrbiMed, Qiming Venture Partners, Chengwei Capital, and Sequoia Capital proving that some investors do not hedge when they see a platform stacked with real horsepower. Jeff He has been steering the business side with the calm precision of someone who has lived the grind across HiFiBiO and Harbour BioMed, while Wei Tang brings 26 years of chemistry and operational muscle that keeps the entire engine humming from New York to Shanghai. That pairing explains why the market keeps doubling down. TandemAI always moved in tandem with where drug discovery was headed, long before the rest of the ecosystem saw the pattern.
What makes this raise interesting is not the number. It is the timing. The company now spans a New York HQ, a Boston AI lab that feels like a command center for molecular modeling, and large scale wet labs in Shanghai and Suzhou running automated chemistry and biology at a pace that is hard to replicate. The merger with Perpetual Medicines earlier this year widened the aperture, giving the team new strength across peptides and antibody peptide conjugates at the exact moment the world realized GLP 1, IL 23, and PCSK9 are only the opening notes of a much bigger therapeutic era. TandemAI is positioned to accelerate that wave, not chase it.
The roster behind this machine is another reason investors do not blink. Alberto Pan strengthens the physics based core, Kerry Blanchard pushes R and D into bolder territory, and Ved Srivastava elevates peptide strategy with the confidence of someone who has already helped bring multiple marketed drugs to life. With Alessandro Monge building commercial lift and Lanny Sun shaping long term strategy, the company operates with a 300+ team that feels aligned around a single purpose. Multiply that with 150+ global partners and more than fifty pipelines moving through the system, and the traction becomes its own proof.
This $22M round accelerates everything. More AI, more modeling power, expanded wet labs, deeper integration across TandemViz, and more capacity for biopharma clients who want speed without sacrificing physics level accuracy. If your drug discovery roadmap is getting heavier by the month, you will want TandemAI in your orbit because this is one platform that grows as fast as the market’s ambition.
Startups Startup Funding Venture Capital Series A AI Biotech Pharma Tech Biopharma Drug Discover Health Tech Healthcare Deep Tech Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
